Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.29% | 60.60% | 175.62% | 636.99% | 11,070.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.29% | 60.60% | 175.62% | 636.99% | 11,070.12% |
| Cost of Revenue | 26.05% | 67.66% | 135.73% | 256.37% | 695.90% |
| Gross Profit | 51.33% | 47.03% | 357.48% | 600.20% | 530.05% |
| SG&A Expenses | -10.56% | -0.11% | 12.96% | 27.64% | 49.77% |
| Depreciation & Amortization | 0.42% | 40.80% | 169.50% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.26% | 18.30% | 27.06% | 32.55% | 30.28% |
| Operating Income | 10.22% | -0.74% | 4.33% | 10.59% | 14.69% |
| Income Before Tax | 6.30% | -4.81% | 4.28% | 12.63% | 16.70% |
| Income Tax Expenses | 72.44% | 26.77% | 88.66% | 103.20% | 33.33% |
| Earnings from Continuing Operations | 5.73% | -5.05% | 3.02% | 11.43% | 16.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.73% | -5.05% | 3.02% | 11.43% | 16.52% |
| EBIT | 10.22% | -0.74% | 4.33% | 10.59% | 14.69% |
| EBITDA | 10.80% | -1.33% | 7.01% | 13.37% | 18.24% |
| EPS Basic | 23.00% | 13.67% | 19.63% | 27.10% | 32.07% |
| Normalized Basic EPS | 26.18% | 16.50% | 20.24% | 26.76% | 30.94% |
| EPS Diluted | 23.00% | 13.67% | 19.63% | 27.10% | 32.07% |
| Normalized Diluted EPS | 26.18% | 16.50% | 20.24% | 26.76% | 30.94% |
| Average Basic Shares Outstanding | 25.35% | 23.22% | 19.46% | 20.21% | 22.51% |
| Average Diluted Shares Outstanding | 25.35% | 23.22% | 19.46% | 20.21% | 22.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |